

CLEAN VERSION OF AMENDMENTS
IN THE SPECIFICATION

Please insert the following at Page 1, above "Background of the Invention":

--CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims priority from Provisional Application Ser No. 60/152,266, filed September 2, 1999.

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

The U.S. Government has certain rights in this invention pursuant to Grant No. R01DK45659 awarded by the National Institute of Health.--

The following Paragraph replaces the paragraph on Page 16, lines 13-22.

--A series of 18-mer phosphothioate oligonucleotides (PTO) were synthesized as potential antisense blocking agents to inhibit the expression of EDG-1 (SEQ ID NO:9) and EDG-3 (SEQ ID NO:10) receptors (Figure 12). The PTOs are designed to bind to the translational initiation site on the mRNA of the EDG-1, -3, and -5 receptors. Sequences represented by SEQ ID NO:3 and SEQ ID NO:6 are the sense sequences for EDG-1 and EDG-3, respectively. Sequences represented by SEQ ID NO: 1 and SEQ ID NO:2 are antisense sequences for EDG-1, wherein the start points differ by three bases. The sequence represented by SEQ ID NO:5 is an antisense sequence for EDG-3. The sequence represented by SEQ ID NO:8 is an antisense sequence for EDG-5. Sequences represented by SEQ ID NO:4 and SEQ ID NO:7 are the "scramble" control sequences for EDG-1 and EDG-3, respectively.—